Rosalind F Sandell1, Rebecca L Boddicker1, Andrew L Feldman2. 1. Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. 2. Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. feldman.andrew@mayo.edu.
Abstract
PURPOSE OF REVIEW: Peripheral T cell lymphomas (PTCLs) are markedly heterogeneous at the clinical, pathological, and molecular levels. This review will discuss genetic findings in PTCL with special emphasis on how they impact lymphoma classification. RECENT FINDINGS: Sequencing studies have identified recurrent genetic alterations in nearly every PTCL subtype. In anaplastic large cell lymphoma, these studies have revealed novel chromosomal rearrangements and mutations that have prognostic significance and may suggest new therapeutic approaches. Angioimmunoblastic T cell lymphoma has been found to have mutations overlapping some cases of PTCL, not otherwise specified with a T follicular helper cell phenotype. Across various subtypes, recurrent mutations and structural alterations affecting genes involved in epigenetic regulation, T cell receptor signaling, and immune response may represent targets for precision therapy approaches. New genetic findings are refining the classification of PTCLs and are beginning to be used clinically for diagnosis, risk stratification, and individualized therapy.
PURPOSE OF REVIEW: Peripheral T cell lymphomas (PTCLs) are markedly heterogeneous at the clinical, pathological, and molecular levels. This review will discuss genetic findings in PTCL with special emphasis on how they impact lymphoma classification. RECENT FINDINGS: Sequencing studies have identified recurrent genetic alterations in nearly every PTCL subtype. In anaplastic large cell lymphoma, these studies have revealed novel chromosomal rearrangements and mutations that have prognostic significance and may suggest new therapeutic approaches. Angioimmunoblastic T cell lymphoma has been found to have mutations overlapping some cases of PTCL, not otherwise specified with a T follicular helper cell phenotype. Across various subtypes, recurrent mutations and structural alterations affecting genes involved in epigenetic regulation, T cell receptor signaling, and immune response may represent targets for precision therapy approaches. New genetic findings are refining the classification of PTCLs and are beginning to be used clinically for diagnosis, risk stratification, and individualized therapy.
Entities:
Keywords:
Anaplastic large cell lymphoma; Angioimmunoblastic T cell lymphoma; Extranodal NK/T cell lymphoma; Molecular genetics; Peripheral T cell lymphoma
Authors: Andrew L Feldman; George Vasmatzis; Yan W Asmann; Jaime Davila; Sumit Middha; Bruce W Eckloff; Sarah H Johnson; Julie C Porcher; Stephen M Ansell; Ariel Caride Journal: Genes Chromosomes Cancer Date: 2013-09-02 Impact factor: 5.006
Authors: Andrew L Feldman; Ahmet Dogan; David I Smith; Mark E Law; Stephen M Ansell; Sarah H Johnson; Julie C Porcher; Nazan Ozsan; Eric D Wieben; Bruce W Eckloff; George Vasmatzis Journal: Blood Date: 2010-10-28 Impact factor: 22.113
Authors: Thirunavukkarasu Velusamy; Mark J Kiel; Anagh A Sahasrabuddhe; Delphine Rolland; Catherine A Dixon; Nathanael G Bailey; Bryan L Betz; Noah A Brown; Alexandra C Hristov; Ryan A Wilcox; Roberto N Miranda; L Jeffrey Medeiros; Yoon K Jeon; Kedar V Inamdar; Megan S Lim; Kojo S J Elenitoba-Johnson Journal: Blood Date: 2014-10-27 Impact factor: 22.113
Authors: Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe Journal: Blood Date: 2016-03-15 Impact factor: 22.113
Authors: S W Morris; M N Kirstein; M B Valentine; K G Dittmer; D N Shapiro; D L Saltman; A T Look Journal: Science Date: 1994-03-04 Impact factor: 47.728
Authors: Martin Bjerregård Pedersen; Stephen Jacques Hamilton-Dutoit; Knud Bendix; Rhett P Ketterling; Patrick P Bedroske; Ivy M Luoma; Christopher A Sattler; Rebecca L Boddicker; N Nora Bennani; Peter Nørgaard; Michael Boe Møller; Torben Steiniche; Francesco d'Amore; Andrew L Feldman Journal: Blood Date: 2017-05-18 Impact factor: 22.113
Authors: Rebecca A Luchtel; Michael T Zimmermann; Guangzhen Hu; Surendra Dasari; Manli Jiang; Naoki Oishi; Hailey K Jacobs; Yu Zeng; Tanya Hundal; Karen L Rech; Rhett P Ketterling; Jeong-Heon Lee; Bruce W Eckloff; Huihuang Yan; Krutika S Gaonkar; Shulan Tian; Zhenqing Ye; Marshall E Kadin; Jagmohan Sidhu; Liuyan Jiang; Jesse Voss; Brian K Link; Sergei I Syrbu; Fabio Facchetti; N Nora Bennani; Susan L Slager; Tamas Ordog; Jean-Pierre Kocher; James R Cerhan; Stephen M Ansell; Andrew L Feldman Journal: Blood Date: 2019-05-17 Impact factor: 22.113
Authors: Abhishek Niroula; Aswin Sekar; Mark A Murakami; Mark Trinder; Mridul Agrawal; Waihay J Wong; Alexander G Bick; Md Mesbah Uddin; Christopher J Gibson; Gabriel K Griffin; Michael C Honigberg; Seyedeh M Zekavat; Kaavya Paruchuri; Pradeep Natarajan; Benjamin L Ebert Journal: Nat Med Date: 2021-10-18 Impact factor: 53.440
Authors: Matthew J Maurer; Fredrik Ellin; Line Srour; Mats Jerkeman; N Nora Bennani; Joseph M Connors; Graham W Slack; Karin E Smedby; Stephen M Ansell; Brian K Link; James R Cerhan; Thomas Relander; Kerry J Savage; Andrew L Feldman Journal: J Clin Oncol Date: 2017-10-26 Impact factor: 44.544